Collaboration Arrangements (Tables)

12 Months Ended

Dec. 31, 2012

Collaboration Arrangements

Schedule of common stock shares purchased in private placements by the affiliate of GSK

	Through December 31, 2012
	Common Stock Shares Purchased		Aggregate Amounts (in thousands)
Purchase dates
February 18, 2011		152,278	$	3,609
May 3, 2011		261,299	$	6,689
August 2, 2011		102,466	$	2,020
November 1, 2011		58,411	$	1,298
February 14, 2012		88,468	$	1,603
August 3, 2012		316,334	$	8,924
November 2, 2012		280,348	$	6,266

Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements

	Year Ended December 31,
(in thousands)	2012		2011		2010
LABA collaboration(1)	$	3,629	$	4,718	$	5,081
Strategic alliance agreement		—		1,858		2,738
Strategic alliance—MABA program license(2)		1,984		3,082		2,007
Total revenue	$	5,613	$	9,658	$	9,826

(1)

The Company revised the estimated performance period for the LABA program based on its progress in the fourth quarter of 2011, resulting in an increase to net loss of $0.4 million for the year ended December 31, 2011. The Company does not expect that the revision will have a material impact on future revenue recognized under this program.

(2)

The Company revised the estimated performance period for the MABA program based on its progress as follows: (i) in the first quarter of 2010, resulting in an increase to net loss of $1.0 million for the year ended December 31, 2010; (ii) in the fourth quarter of 2011, resulting in an increase to net loss of $0.2 million for the year ended December 31, 2011; and (iii) in the fourth quarter of 2012, resulting in an increase to net loss of $0.1 million for the year ended December 31, 2012. The Company does not expect that the revision will have a material impact on future revenue recognized under this program.

Schedule of revenue recognized under the Astellas collaboration agreement

	Year Ended December 31,
(in thousands)	2012			2011			2010
Recognition of deferred revenue	$	125,819		$	—		$	—
Amortization of deferred revenue		—			12,975			12,975
Royalties from net sales of VIBATIV®		—			2,422			1,123
Proceeds from VIBATIV® delivered to Astellas		—			1,171			2,058
Cost of VIBATIV® delivered to Astellas		—			(1,177	)		(938	)
Cost of unrealizable VIBATIV® inventories		—			(537	)		(821	)
Astellas-labeled product sales allowance		(31	)		—			—
Total net revenue	$	125,788		$	14,854		$	14,397